The value of C-reactive protein in the evaluation of the prognosis of renal cancer

doi:10.3760/cma.j.issn.1673-422X.2014.05.013

Abstract

Abstract: ncreasing evidence has proved that inflammation plays an extremely important role in tumorigenesis. As the most representative biomarker for inflammation, Creactive protein (CRP) has been considered to be critically associated with the prognosis of a variety of malignant tumors, like renal cancer.Numerous studies have shown that CRP is a significant prognostic factor for renal cancer patients treated with surgery, cytokine therapy or moleculartargeted therapy, and CRP has been incorporated into some prognostic algorithms for renal cancer.

Key words: Kidney neoplasms, Inflammation, C-reactive protein, Prognosis

Jiang Guangliang, Hu Qingfeng, Xu Ke. The value of C-reactive protein in the evaluation of the prognosis of renal cancer[J]. Journal of International Oncology, 2014, 41(5): 361-363.

References

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62(1):10-29. ［2］ Mantovani A, Allavena P, Sica A, et al. Cancerrelated inflammation［J］. Nature, 2008, 454(7203):436-444. ［3］ Allavena P, Garlanda C, Borrello MG, et al. Pathways connecting inflammation and cancer［J］. Curr Opin Genet Dev, 2008, 18(1):3-10. ［4］ Eiró N, Vizoso FJ. Inflammation and cancer［J］. World J Gastrointest Surg, 2012, 4(3):62-72. ［5］蒋春灵, 李金高. C反应蛋白在肿瘤临床中的意义［J］. 国际肿瘤学杂志, 2009, 36(2):99-102. ［6］ Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer［J］. Cell, 2010, 140(6):883899. ［7］ Yang Y, Mao QZ, Li HZ, et al. Clinical features of urological malignancies with paraneoplastic syndromes［J］. Zhonghua Yi Xue Za Zhi, 2010, 90(48):3411-3414. ［8］ Bottazzi B, Doni A, Garlanda C, et al. An integrated view of humoral innate immunity: pentraxins as a paradigm［J］. Annu Rev Immunol, 2010, 28:157-183. ［9］ Howren MB, Lamkin DM, Suls J. Associations of depression with Creactive protein, IL1, and IL6: a metaanalysis［J］. Psychosom Med, 2009, 71(2):171-186. ［10］ Lee S, Choe JW, Kim HK, et al. Highsensitivity Creactive protein and cancer［J］. J Epidemiol, 2011, 21(3):161-168. ［11］ Saito K, Kihara K. Role of Creactive protein as a biomarker for renal cell carcinoma［J］. Expert Rev Anticancer Ther, 2010, 10(12):1979-1989. ［12］ Lamb GW, Mcmillan DC, Ramsey S, et al. The relationship between the preoperative systemic inflammatory response and cancerspecific survival in patients undergoing potentially curative resection for renal clear cell cancer［J］. Br J Cancer, 2006, 94(6):781-784. ［13］ Ito K, Yoshii H, Asakuma J, et al. Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens［J］. Jpn J Clin Oncol, 2009, 39(9):588-594. ［14］ Ito K, Asano T, Yoshii H, et al. Impact of thrombocytosis and Creactive protein elevation on the prognosis for patients with renal cell carcinoma［J］. Int J Urol, 2006, 13(11):1365-1370. ［15］ Naito S, Yamamoto N, Takayama T, et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients［J］. Eur Urol, 2010, 57(2):317-325. ［16］ Saito K, Tatokoro M, Fujii Y, et al. Impact of Creactive protein kinetics on survival of patients with metastatic renal cell carcinoma［J］. Eur Urol, 2009, 55(5):1145-1153. ［17］ Shinohara N, Kumagai A, Kanagawa K, et al. Multicenter phase Ⅱ trial of combination therapy with meloxicam, a cox2 inhibitor, and natural interferonalpha for metastatic renal cell carcinoma［J］. Jpn J Clin Oncol, 2009, 39(11):720-726. ［18］ Kamba T, Yamasaki T, Teramukai S, et al. Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial SloanKettering Cancer Center intermediate risk features by modern strategy including moleculartargeted therapy in clinical practice［J］. Int J Clin Oncol, 2013, In press. ［19］ Fujita T, Iwamura M, Ishii D, et al. Creactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib［J］. Int J Urol, 2012, 19(10):908-913. ［20］ Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammationbased prognostic score in patients with metastatic renal cancer［J］. Cancer, 2007, 109(2):205-212. ［21］ Iimura Y, Saito K, Fujii Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum Creactive protein and TNM classification: the TNMC score［J］. J Urol, 2009, 181(3):1004-1012.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[4]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[5]	Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei. Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction [J]. Journal of International Oncology, 2024, 51(4): 193-197.
[6]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[7]	Yao Yixin, Shen Yulin. Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE [J]. Journal of International Oncology, 2024, 51(4): 217-222.
[8]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[9]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[10]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[11]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[12]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[13]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[14]	Wang Xiao, Li Ying, Luo Yujie, Jin Shu. Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model [J]. Journal of International Oncology, 2023, 50(8): 463-469.
[15]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.